Date: 2026-09-15 Source: Email from michael@generationlab.co to SAFE holders including michael@ryevalley.co Thread: “GenLab Update and Raise”
Signal
Generation Lab sent an investor update announcing their Series A kickoff. Michael holds a SAFE in GenLab (angel position).
Key milestones since mid-April (5 months):
- Physician-led human trial underway: their drug “One Generation” (FDA-approved compounds in novel combination) being injected into 8 humans; initial data reported as “extremely positive”
- First annual Translating Rejuvenation Symposium held with world-renowned scientists
- Series A is now launching
Business Fact
- Michael is a SAFE holder in Generation Lab; this email is a portfolio company update.
- Company is raising Series A as of Sep 15, 2026.
- Progress: moved from cell studies to human trials; conference organized.
- No financial terms disclosed in the email snippet.
Watch
- Series A terms if Michael is given pro-rata or co-invest rights
- Whether Michael wants to participate in the round or connect them with his network